1 Min Read
Nov 8 (Reuters) - Zosano Pharma Corp
* Zosano Pharma announces initiation of long-term safety study for M207 as an acute treatment of migraine Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.